Andere Kunden interessierten sich auch für
![Effetti degli ACE-inibitori e dei beta-bloccanti nella prevenzione del cancro]( "Effetti degli ACE-inibitori e dei beta-bloccanti nella prevenzione del cancro")
Effetti degli ACE-inibitori e dei beta-bloccanti nella prevenzione del cancro29,99 €![Mechanisms of ACE inhibitors in preventing MI and heart failure]( "Mechanisms of ACE inhibitors in preventing MI and heart failure")
Mechanisms of ACE inhibitors in preventing MI and heart failure32,99 €![Heart Failure in the Child and Young Adult]( "Heart Failure in the Child and Young Adult")
Heart Failure in the Child and Young Adult144,99 €![Beta blockers use in cardiac failure]( "Beta blockers use in cardiac failure")
Beta blockers use in cardiac failure25,99 €![Vliqnie ingibitorow APF i beta-blokatorow na profilaktiku raka]( "Vliqnie ingibitorow APF i beta-blokatorow na profilaktiku raka")
Vliqnie ingibitorow APF i beta-blokatorow na profilaktiku raka13,99 €![Unraveling Medical Therapeutics]( "Unraveling Medical Therapeutics")
Unraveling Medical Therapeutics23,99 €![Kinase Inhibitors]( "Kinase Inhibitors")
Kinase Inhibitors29,99 €
Survival of cancer patients has improved as a result of the beneficial effect of chemotherapy and monoclonal antibodies directed against human epidermal growth factor receptor 2 such as trastuzumab. The treatments, however, are accompanied by known cardiotoxic effects, which in some may be mild and asymptomatic but in their most severe forms can lead to heart failure which seriously worsens the prognosis. Several cancer treatments have been associated with the potential risk of cardiotoxicity, including: anthracyclines, 5-fluorouracil, cyclophosphamide, tyrosine kinase inhibitors, vascular endothelial growth factor, immune checkpoint inhibitors, HER-2 antagonists, as well as radiotherapy. Most of the published data on cardiotoxicity, however, are focused on anthracyclines and trastuzumab. This paper will discuss the usefulness of beta-blockers alone and in combination therapy with converting enzyme inhibitors (ACE inhibitors) for the prevention of cardiotoxicity in cancer patients treated with anthracyclines and trastuzumab.